Mar 29, 2014

Metal complexes designed to bind to amyloid-β for the diagnosis and treatment of Alzheimer's disease

Chemical Society Reviews
David J HaynePaul S Donnelly

Abstract

Alzheimer's disease is the most common form of age-related neurodegenerative dementia. The disease is characterised by the presence of plaques in the cerebral cortex. The major constituent of these plaques is aggregated amyloid-β peptide. This review focuses on the molecular aspects of metal complexes designed to bind to amyloid-β. The development of radioactive metal-based complexes of copper and technetium designed as diagnostic imaging agents to detect amyloid burden in the brain is discussed. Separate sections of the review discuss the use of luminescent metal complexes to act as non-conventional probes of amyloid formation and recent research into the use of metal complexes as inhibitors of amyloid formation and toxicity.

Mentioned in this Paper

Familial Alzheimer Disease (FAD)
APP protein, human
Complex (molecular entity)
Aggregation
Brain
Alzheimer's Disease
Plasma Protein Binding Capacity
Copper
Amyloid Deposition
Senile Plaques

Related Feeds

Alzheimer's Disease: Abeta

Alzheimer's disease (AD) is a chronic neurodegenerative disease associated with accumulation of amyloid plaques, which are comprised of amyloid beta. Here is the latest research in this field.

Alzheimer's Disease: APP

Amyloid precursor protein proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques. Here is the latest research.